Chelsea R Hutch1, Karen Roelofs1, April Haller2, Joyce Sorrell2, Kyle Leix1, David D D'Alessio3, Robert Augustin4, Randy J Seeley1, Thomas Klein4, Darleen A Sandoval5. 1. Department of Surgery, University of Michigan, 2800 Plymouth Road, Ann Arbor, MI, 48109, USA. 2. Department of Internal Medicine-Endocrinology, Diabetes, and Metabolism, University of Cincinnati, Cincinnati, OH, USA. 3. Division of Endocrinology, Metabolism, and Nutrition, Duke University Medical Center, Durham, NC, USA. 4. Cardiometabolic Diseases Research (Biberach), Boehringer Ingelheim, Ingelheim am Rhein, Germany. 5. Department of Surgery, University of Michigan, 2800 Plymouth Road, Ann Arbor, MI, 48109, USA. darleens@med.umich.edu.
Abstract
AIMS/HYPOTHESIS: Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are two peptides that function to promote insulin secretion. Dipeptidyl peptidase-4 (DPP-4) inhibitors increase the bioavailability of both GLP-1 and GIP but the dogma continues to be that it is the increase in GLP-1 that contributes to the improved glucose homeostasis. We have previously demonstrated that pancreatic rather than intestinal GLP-1 is necessary for improvements in glucose homeostasis in mice. Therefore, we hypothesise that a combination of pancreatic GLP-1 and GIP is necessary for the full effect of DPP-4 inhibitors on glucose homeostasis. METHODS: We have genetically engineered mouse lines in which the preproglucagon gene (Gcg) is absent in the entire body (GcgRAΔNull) or is expressed exclusively in the intestine (GcgRAΔVilCre) or pancreas and duodenum (GcgRAΔPDX1Cre). These mice were used to examine oral glucose tolerance and GLP-1 and GIP responses to a DPP-4 inhibitor alone, or in combination with incretin receptor antagonists. RESULTS: Administration of the DPP-4 inhibitor, linagliptin, improved glucose tolerance in GcgRAΔNull mice and control littermates and in GcgRAΔVilCre and GcgRAΔPDX1Cre mice. The potent GLP-1 receptor antagonist, exendin-[9-39] (Ex9), blunted improvements in glucose tolerance in linagliptin-treated control mice and in GcgRAΔPDX1Cre mice. Ex9 had no effect on glucose tolerance in linagliptin-treated GcgRAΔNull or in GcgRAΔVilCre mice. In addition to GLP-1, linagliptin also increased postprandial plasma levels of GIP to a similar degree in all genotypes. When linagliptin was co-administered with a GIP-antagonising antibody, the impact of linagliptin was partially blunted in wild-type mice and was fully blocked in GcgRAΔNull mice. CONCLUSIONS/ INTERPRETATION: Taken together, these data suggest that increases in pancreatic GLP-1 and GIP are necessary for the full effect of DPP-4 inhibitors on glucose tolerance.
AIMS/HYPOTHESIS: Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are two peptides that function to promote insulin secretion. Dipeptidyl peptidase-4 (DPP-4) inhibitors increase the bioavailability of both GLP-1 and GIP but the dogma continues to be that it is the increase in GLP-1 that contributes to the improved glucose homeostasis. We have previously demonstrated that pancreatic rather than intestinal GLP-1 is necessary for improvements in glucose homeostasis in mice. Therefore, we hypothesise that a combination of pancreaticGLP-1 and GIP is necessary for the full effect of DPP-4 inhibitors on glucose homeostasis. METHODS: We have genetically engineered mouse lines in which the preproglucagon gene (Gcg) is absent in the entire body (GcgRAΔNull) or is expressed exclusively in the intestine (GcgRAΔVilCre) or pancreas and duodenum (GcgRAΔPDX1Cre). These mice were used to examine oral glucose tolerance and GLP-1 and GIP responses to a DPP-4 inhibitor alone, or in combination with incretin receptor antagonists. RESULTS: Administration of the DPP-4 inhibitor, linagliptin, improved glucose tolerance in GcgRAΔNull mice and control littermates and in GcgRAΔVilCre and GcgRAΔPDX1Cremice. The potent GLP-1 receptor antagonist, exendin-[9-39] (Ex9), blunted improvements in glucose tolerance in linagliptin-treated control mice and in GcgRAΔPDX1Cremice. Ex9 had no effect on glucose tolerance in linagliptin-treated GcgRAΔNull or in GcgRAΔVilCre mice. In addition to GLP-1, linagliptin also increased postprandial plasma levels of GIP to a similar degree in all genotypes. When linagliptin was co-administered with a GIP-antagonising antibody, the impact of linagliptin was partially blunted in wild-type mice and was fully blocked in GcgRAΔNull mice. CONCLUSIONS/ INTERPRETATION: Taken together, these data suggest that increases in pancreaticGLP-1 and GIP are necessary for the full effect of DPP-4 inhibitors on glucose tolerance.
Authors: Erin E Mulvihill; Elodie M Varin; Bojana Gladanac; Jonathan E Campbell; John R Ussher; Laurie L Baggio; Bernardo Yusta; Jennifer Ayala; Melissa A Burmeister; Dianne Matthews; K W Annie Bang; Julio E Ayala; Daniel J Drucker Journal: Cell Metab Date: 2016-11-10 Impact factor: 27.287
Authors: Megan E Capozzi; Berit Svendsen; Sara E Encisco; Sophie L Lewandowski; Mackenzie D Martin; Haopeng Lin; Justin L Jaffe; Reilly W Coch; Jonathan M Haldeman; Patrick E MacDonald; Matthew J Merrins; David A D'Alessio; Jonathan E Campbell Journal: JCI Insight Date: 2019-03-07
Authors: Hua V Lin; Jingru Wang; Jie Wang; Weiji Li; Xuesong Wang; James T Alston; Melissa K Thomas; Daniel A Briere; Samreen K Syed; Alexander M Efanov Journal: Mol Metab Date: 2018-02-23 Impact factor: 7.422
Authors: Jo E Lewis; Emily L Miedzybrodzka; Rachel E Foreman; Orla R M Woodward; Richard G Kay; Deborah A Goldspink; Fiona M Gribble; Frank Reimann Journal: Diabetologia Date: 2020-04-27 Impact factor: 10.122
Authors: Arnaldo Henrique de Souza; Jiayin Tang; Amanjot Kaur Yadev; Samuel T Saghafi; Carly R Kibbe; Amelia K Linnemann; Matthew J Merrins; Dawn Belt Davis Journal: Sci Rep Date: 2020-02-18 Impact factor: 4.379
Authors: Mridusmita Saikia; Marlena M Holter; Leanne R Donahue; Isaac S Lee; Qiaonan C Zheng; Journey L Wise; Jenna E Todero; Daryl J Phuong; Darline Garibay; Reilly Coch; Kyle W Sloop; Adolfo Garcia-Ocana; Charles G Danko; Bethany P Cummings Journal: JCI Insight Date: 2021-02-08